PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Core Insights - PureTech's founded entity Gallop Oncology has announced positive initial topline data for LYT-200 in the treatment of relapsed/refractory acute myeloid leukemia [1] Group 1 - The initial data indicates that LYT-200 shows promise in addressing relapsed/refractory acute myeloid leukemia, a condition with significant unmet medical needs [1] - The announcement highlights the potential of LYT-200 to improve patient outcomes in a challenging therapeutic area [1]